DJIA 16,979.13 59.54 0.35%
NASDAQ 4,526.48 -1.03 -0.02%
S&P 500 1,986.51 4.91 0.25%
market minute promo

Seattle Genetics (NASDAQ: SGEN)



company name or ticker

Why Manitowoc, Endocyte, and Seattle Genetics Tumbled Today

Stocks generally disappointed investors on Friday as the Ukrainian situation trumped strong jobs data, but these three stocks performed much worse than the broader market. Find out why.

Why Seattle Genetics, Inc. Shares Soured

Seattle Genetics shares sink despite topping Wall Street's expectations in the first quarter. See what has investors up in arms and what you should do about it.

Seattle Genetics Management Discusses Q1 2014 Results - Earnings Call Transcript

Seattle Genetics' Revenue Rises 19% on Adcetris Sales Growth

Antibody-drug conjugate developer Seattle Genetics delivers strong sales gains from lead drug Adcetris despite a flat year-over-year net loss.

Seattle Genetics, Inc. Discusses Q1 2014 Results (Webcast)

Today's Biotech Stocks to Watch: BioMarin Pharmaceutical Inc, InterMune, Inc. and Seattle Genetics I

Today's top stories in health care and biotech.

First Week of SGEN December 20th Options Trading

Seattle Genetics Earns Milestone Payment - Analyst Blog

Seattle Genetics Achieves Milestones Under Collaboration with Takeda for Achieving First Commercial

Seattle Genetics Achieves Milestones Under Collaboration with Takeda for Achieving First Commercial Sales of ADCETRIS

5 Biotechs With Prostate Cancer Treatments Worth Watching

Prostate cancer is now the second leading cause of cancer-specific deaths among men in the United States. Here are five biotechs aiming to meet this challenge with a diversity of promising new therapies.
See More Articles...